HAWK Biosystems is a biotechnology start-up created in 2016, which has developed QF-Pro®, a highly sensitive and specific microscopy platform for the quantification of novel biomarkers. This platform is designed to quantify the activation states of proteins and the formation of protein complexes both in cell cultures and in tumor biopsies. HAWK Biosystems’ mission is to be a leading platform in the diagnosis and prognosis of cancer, significantly increasing the precision in the treatment of patients. The QF-Pro® platform is based on Förster resonance energy transfer (FRET) mechanism between chromophores which, for the first time, allows its use in pathological samples, due to its high signal-to-noise ratio. This platform allows the analysis of biopsies from hospital oncology units, as well as tumor samples from various trials established in pharmaceutical companies.
GLYCOSCIENCE
30 July, 2021